Trial Profile
A Single Arm, Open Label, Multicenter, Phase II Study of Famitinib in Patients With Gastrointestinal Stromal Tumor
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Jun 2019
Price :
$35
*
At a glance
- Drugs Famitinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
- 16 Apr 2018 Planned End Date changed from 1 Jun 2016 to 1 Jun 2019.
- 16 Apr 2018 Planned primary completion date changed from 1 Jun 2016 to 1 Dec 2018.
- 01 Feb 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Jun 2016, according to ClinicalTrials.gov record.